{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:13:41Z","timestamp":1758636821529},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite the advances of potent oral P2Y<jats:sub>12<\/jats:sub>inhibitors, their onset of action is delayed, which might have a negative impact on clinical outcome in patients undergoing percutaneous coronary intervention (PCI). Trials conducted in the United States of America have identified cangrelor as a potent and rapid-acting intravenous P2Y<jats:sub>12<\/jats:sub>inhibitor, which has the potential of reducing ischemic events in these patients without an increase in the bleeding. As cangrelor is rarely used in The Netherlands, we conducted a nationwide registry to provide an insight into the use of cangrelor in the management of patients with suboptimal platelet inhibition undergoing (primary) PCI (the Dutch Cangrelor Registry).<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design<\/jats:title><jats:p>The Cangrelor Registry is a prospective, observational, multicenter, single-arm registry with cangrelor administered pre-PCI in: (1) P2Y<jats:sub>12<\/jats:sub>naive patients with ad-hoc PCI, (2) patients with STEMI\/NSTEMI with suboptimal P2Y<jats:sub>12<\/jats:sub>inhibition including (3) stable resuscitated\/defibrillated patients with out-of-hospital cardiac arrest (OHCA) due to acute ischemia and (4) STEMI\/NSTEMI patients with a high thrombotic burden. Primary endpoint is 48\u00a0h Net Adverse Clinical Events (NACE), which is a composite endpoint of all-cause death, recurrent myocardial infarction (MI), target vessel revascularization (TVR), stroke, stent thrombosis (ST) and BARC 2-3-5 bleeding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>The Dutch Cangrelor Registry will assess the feasibility and safety of cangrelor in patients with suboptimal P2Y<jats:sub>12<\/jats:sub>inhibition undergoing (primary) PCI in the setting of acute coronary syndrome (ACS) and stable coronary artery disease (CAD) in the Netherlands.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12872-021-02093-4","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T14:14:33Z","timestamp":1623507273000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry"],"prefix":"10.1186","volume":"21","author":[{"given":"A.","family":"Selvarajah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H.","family":"Tavenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"Bor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Houben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rasoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Teeuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Hofma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lipsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A. H.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M. ten","family":"Berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W. J.","family":"van \u2018t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Hermanides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"key":"2093_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","volume":"14","author":"F Franchi","year":"2017","unstructured":"Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol. 2017;14:361\u201379. https:\/\/doi.org\/10.1038\/nrcardio.2017.18.","journal-title":"Nat Rev Cardiol"},{"key":"2093_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Bryne RA, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart. 2017. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart"},{"key":"2093_CR3","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823ba622","volume":"124","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC, et al. ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:2574-e651. https:\/\/doi.org\/10.1161\/CIR.0b013e31823ba622.","journal-title":"Circulation"},{"issue":"pt A","key":"2093_CR4","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.jacc.2018.09.057","volume":"72","author":"D Capadanno","year":"2018","unstructured":"Capadanno D, Alfonso F, Levine GN, et al. ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J AM Coll Cardiol. 2018;72(pt A):2915\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057.","journal-title":"J AM Coll Cardiol"},{"key":"2093_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","volume":"375","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy of acute coronary syndromes (PLATO): a randomized double blind study. Lancet. 2010;375:283\u201393.","journal-title":"Lancet"},{"key":"2093_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j\/jcin2015.02.030","volume":"8","author":"F Franchi","year":"2015","unstructured":"Franchi F, Rollini F, Cho JR, et al. Impact of escalating loading dose of regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015;8:1457\u201367. https:\/\/doi.org\/10.1016\/j\/jcin2015.02.030.","journal-title":"JACC Cardiovasc Interv"},{"key":"2093_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1116\/CIRCINTERVENTIONS.113.001118","volume":"7","author":"D Alexopoulos","year":"2014","unstructured":"Alexopoulos D, Makris G, Xanthopoulou I, et al. Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamics study. Circ Cardiovasc Interv. 2014;7:233\u20139. https:\/\/doi.org\/10.1116\/CIRCINTERVENTIONS.113.001118.","journal-title":"Circ Cardiovasc Interv"},{"issue":"6","key":"2093_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.thromres.2008.01.021","volume":"122","author":"AA Heestermans","year":"2008","unstructured":"Heestermans AA, van Werkum JW, Taubert D, et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res. 2008;122(6):776\u201381.","journal-title":"Thromb Res"},{"issue":"3","key":"2093_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00228-012-1360-0","volume":"69","author":"L Souckova","year":"2013","unstructured":"Souckova L, Opatnlova R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013;69(3):309\u201317.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2093_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","volume":"37","author":"J Kubica","year":"2016","unstructured":"Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37(3):245\u201352.","journal-title":"Eur Heart J"},{"issue":"1","key":"2093_CR11","doi-asserted-by":"crossref","first-page":"e001593","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","volume":"8","author":"G Parodi","year":"2014","unstructured":"Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-segment acute myocardial infarction undergoing primary percutaneous intervention. Circ Cardiovasc Interv. 2014;8(1):e001593.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"2093_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","volume":"137","author":"JW McEVoy","year":"2018","unstructured":"McEVoy JW, Ibrahim K, Kickler TS, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous intervention: the PACIFY randomized clinical trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl). Circulation. 2018;137(3):307\u20139.","journal-title":"Circulation"},{"issue":"1","key":"2093_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","volume":"34","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44\u201355.","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"2093_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1586\/erc.09.101","volume":"7","author":"JL Ferreiro","year":"2009","unstructured":"Ferreiro JL, Ueno M, Angiolillo DJ, et al. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther. 2009;7(10):1195\u2013201.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"10","key":"2093_CR15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","volume":"11","author":"F Franchi","year":"2013","unstructured":"Franchi F, Rollini F, Muniz-Lozano A, et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013;11(10):1279\u201391.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"14","key":"2093_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303\u201313.","journal-title":"N Engl J Med"},{"key":"2093_CR17","doi-asserted-by":"crossref","unstructured":"Harrington RA, Stone GW, Mc Nulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318\u201329.","DOI":"10.1056\/NEJMoa0908628"},{"issue":"24","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI on ischemic events. N Engl J Med. 2009;361(24):2330\u201341.","journal-title":"N Engl J Med"},{"issue":"9909","key":"2093_CR19","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981\u201392.","journal-title":"Lancet"},{"issue":"3","key":"2093_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.amjcard.2017.04.034","volume":"120","author":"HA Badreldin","year":"2017","unstructured":"Badreldin HA, Carter D, Cook BM, et al. Safety and tolerability of transitioning from cangrelor to ticagrelor in patients who underwent percutaneous coronary intervention. Am J Cardiol. 2017;120(3):359\u201361.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2093_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","volume":"26","author":"DJ Schneider","year":"2015","unstructured":"Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42\u20138.","journal-title":"Coron Artery Dis"},{"issue":"4","key":"2093_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","volume":"7","author":"DJ Schneider","year":"2014","unstructured":"Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435\u201342.","journal-title":"JACC Cardiovasc Interv"},{"key":"2093_CR23","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","volume":"139","author":"F Franchi","year":"2019","unstructured":"Franchi F, Rollini F, Rivas A, et al. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment\u2013elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation. 2019;139:1661\u201370.","journal-title":"Circulation"},{"key":"2093_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"SR Steinhubl","year":"2008","unstructured":"Steinhubl SR, Oh JJ, Oestreich JH, et al. Transitioning Patients From Cangrelor to Clopidogrel: Pharmacodynamic Evidence of a Competitive Effect. Thromb Res. 2008;121:527\u201334.","journal-title":"Thromb Res"},{"issue":"3","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","volume":"40","author":"K Thygesen","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffes AS, ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018;40(3):237\u201369.","journal-title":"Eur Heart J"},{"key":"2093_CR26","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"issue":"23","key":"2093_CR27","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clincial trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347.","journal-title":"Circulation"},{"key":"2093_CR28","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569\u2013619.","journal-title":"Eur Heart J"},{"key":"2093_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jacc.2007.04.059","volume":"50","author":"G Sianos","year":"2007","unstructured":"Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573\u201383.","journal-title":"J Am Coll Cardiol"},{"key":"2093_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/eurheartj\/ehn594","volume":"30","author":"M Napodano","year":"2009","unstructured":"Napodano M, Ramondo A, Tarantini G, et al. Predictors and time-related impact of distal embolization during primary angioplasty. Eur Heart J. 2009;30:305\u201313.","journal-title":"Eur Heart J"},{"key":"2093_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/eurheartj\/ehp033","volume":"30","author":"ML Fokkema","year":"2009","unstructured":"Fokkema ML, Vlaar PJ, Svilaas T, et al. Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. Eur Heart J. 2009;30:908\u201315.","journal-title":"Eur Heart J"},{"key":"2093_CR32","first-page":"6B","volume":"22","author":"G Sianos","year":"2010","unstructured":"Sianos G, Papafaklis MI, Serruys PW. Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol. 2010;22:6B-14B.","journal-title":"J Invasive Cardiol"},{"key":"2093_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0002-9149(01)02040-9","volume":"88","author":"M Singh","year":"2001","unstructured":"Singh M, Berger PB, Ting HH, et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol. 2001;88:1091\u20136.","journal-title":"Am J Cardiol"},{"key":"2093_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0002-9149(02)03233-2","volume":"91","author":"D Fukuda","year":"2003","unstructured":"Fukuda D, Tanaka A, Shimada K, et al. Predicting angiographic distal embolization following percutaneous coronary intervention in patients with acute myocardial infarction. Am J Cardiol. 2003;91:403\u20137.","journal-title":"Am J Cardiol"},{"key":"2093_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","volume":"170","author":"D Alexopoulos","year":"2015","unstructured":"Alexopoulos D, Bhatt DL, Hamm CW, et al. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J. 2015;170:3\u201312.","journal-title":"Am Heart J"},{"key":"2093_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","volume":"55","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Barampoutis N, Gkizas V, et al. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic \/pharmacodynamic study. Clin Pharmacokinet. 2016;55:359\u201367.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2093_CR37","doi-asserted-by":"publisher","first-page":"E1090","DOI":"10.21037\/jtd.2016.08.31","volume":"8","author":"A Neylon","year":"2016","unstructured":"Neylon A, Garot P, et al. Antiplatelet agents in out of hospital cardiac arrest survivors does an impaired biological response increase stent thrombosis risk? J Thorac Dis. 2016;8(9):E1090\u20132.","journal-title":"J Thorac Dis"},{"issue":"3","key":"2093_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265\u201374.","journal-title":"JAMA"},{"key":"2093_CR39","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jcin.2015.04.031","volume":"8","author":"DM Safley","year":"2015","unstructured":"Safley DM, Venkitachalam L, Kennedy KF, Cohen DJ. Impact of glycoprotein IIb\/IIIa inhibition in contemporary percutaneous coronary intervention for acute coronary syndromes: insights from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2015;8:1574\u201382.","journal-title":"JACC Cardiovasc Interv"},{"key":"2093_CR40","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/1753944713487781","volume":"7","author":"A Mu\u00f1iz-Lozano","year":"2013","unstructured":"Mu\u00f1iz-Lozano A, Rollini F, Franchi F, Angiolillo DJ. Update on platelet glycoprotein IIb\/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013;7:197\u2013213.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"5","key":"2093_CR41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","volume":"142","author":"G Gargiulo","year":"2020","unstructured":"Gargiulo G, Esposito G, et al. Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with st-segment\u2013elevation myocardial infarction. Circulation. 2020;142(5):441\u201354.","journal-title":"Circulation"},{"key":"2093_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s40265-015-0445-3","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Cangrelor: a review in percutaneous coronary intervention. Drugs 2015;75(12):1425\u201334.","journal-title":"Drugs"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-021-02093-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-021-02093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T22:42:18Z","timestamp":1672440138000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-021-02093-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1186\/s12872-021-02093-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,12]]},"assertion":[{"value":"13 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the institutional ethics committees of each participating hospitals, and all patients will provide written informed consent for the participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"292"}}